Focus research 2022 DIAD team

Theranostic radiolabeled molecules and the concept of optimal exposure

We are developing the concept of optimal plasma exposure, which is well known for ‘classical’ drugs, in the context of vectorized internal radiotherapy and in particular of177 Lu-Dotatate, a somatostatin analog prescribed for the treatment of endocrine tumors. We have shown that the nature of the amino acids administered simultaneously with this radiolabeled molecule to reduce renal toxicity has an impact on exposure to this drug. In general, we are studying the pharmacokinetic parameters of 177 Lu-Dotatate and their variability in two clinical trials: a phase 1 study in oncopediatrics and a study in adults investigating tumor radiosensitivity factors.

To find out more about the IUCT-Oncopole and CRCT-Oncopole research focuses, please click here